PSTX Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

$7.08  -0.14 (-1.94%)
As of 12/03/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  62,506,279
Average volume:  181,669
Market cap:   $451,295,334
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    73730P108
ISIN:        US73730P1084
Sedol:      BJ4SF41
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.94
PS ratio:   0.00
Return on equity:   -108.28%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy